Alliance Pharma PLC Hardman & Co issues research report
April 20 2015 - 2:00AM
RNS Non-Regulatory
TIDMAPH
Alliance Pharma PLC
20 April 2015
Hardman & Co issues research report on Alliance Pharma
Set for resumption in growth: Alliance Pharma released a solid
set of full year numbers, demonstrating the resilience of its
underlying core businesses. As the company emerges from the loss of
its toxicology product the business appears ready to resume growth
with FY 14 underlying pre-tax profit growth having been 15%. The
2015 acquisition of MacuVision provides an additional franchise
upon which to build. Coupled with a robust balance sheet and the
capacity to fund quite significant opportunities, the outlook for
growth looks better than it has done for 3 years.
Please click here for the full report:
http://www.hardmanandco.com/sites/default/files/research_papers/Alliance%20Pharma%20Finals%20-%2013%20April%202015_Final.pdf
To contact us: Contact: Mark Brewer mb@hardmanandco.com
Hardman & Co Martin Hall mh@hardmanandco.com
11/12 Tokenhouse Telephone: +44 20 7929 3399
Yard Follow us on Twitter @HardmanandCo
London
EC2R 7AS
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFIESTIDLIE
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024